Peter Ujhazy, MD, PhD

Deputy Associate Director

Translational Research Program

Division of Cancer Treatment and Diagnosis,
National Cancer Institute
9609 Medical Center Drive, Room 3W106
MSC 9726
Bethesda, MD 20892
Phone (240) 276-5681
Fax (240) 276-7881
Email: ujhazyp@mail.nih.gov

Portfolios: Epigenetics, Lung, Myeloma, Sarcoma, and Pancreas (PSRC Consortium Only)

Peter Ujhazy has received his Medical Degree at the Comenius University, and his PhD at the Cancer Research Institute of the Slovak Academy of Sciences in Bratislava, Czechoslovakia, where he started his career in the Department of Tumor Immunology. He was involved in the development of diagnostics in blood malignancies, he studied natural immunity in lymphoid malignancies, and gained clinical experience in the adjacent Cancer Center. He worked for 6 years as a Visiting Scientist and later as a Cancer Research Scientist in Dr. Henry Mihich's laboratory at Roswell Park Cancer Institute in Buffalo, NY, USA and published extensively on chemo-immunotherapy and multidrug resistance. After a short stay in the biotech company Biotech Research Laboratories in the Washington, DC metropolitan area, he decided not to pursue a career in industry and accepted a position in Dr. Irvin Arias' laboratory in the Department of Physiology, Tufts University in Boston, MA, where he studied the physiologic role of ATP-dependent transporters. In 2001, Dr. Ujhazy accepted a position in the National Cancer Institute's Organ Systems Branch that managed Specialized Programs of Research Excellence (SPOREs). Working with SPOREs grants brought him closer to the ultimate goal of his original training - that is to help patients and populations at risk of cancer. Dr. Ujhazy has served as the Program Director for Lung, Leukemia, Lymphoma, Myeloma, Sarcoma, GI, Pancreas, Head & Neck, and Brain Tumor SPOREs. Currently, he is in charge of SPOREs in lung, sarcoma, myeloma, and epigenetics. He is also involved as a Project Scientist in the Small Cell Lung Cancer and in the Pancreatic Ductal Adenocarcinoma Stromal Reprograming (PSRC) Consortia. His other duties include serving on various NCI committees and working groups.